UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/508,759	09/22/2004	Hyo Jeong Hong	DE1586	9699	
1109 ANDERSON	7590 08/22/2007 KILL & OLICK, P.C.	EXAMINER			
1251 AVENU	1251 AVENUE OF THE AMERICAS			BOESEN, AGNIESZKA	
NEW YORK,,	NY 10020-1182		ART UNIT PAPER NUMBER		
			1648		
			NAME DAME	DEL IVERY MODE	
			MAIL DATE	DELIVERY MODE	
			08/22/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.	Applicant(s)			
		10/508,759	HONG ET AL.			
Office Act	ion Summary	Examiner	Art Unit			
		Agnieszka Boesen	1648			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
'= '	Responsive to communication(s) filed on <u>22 September 2004</u> .					
2a) ☐ This action is FI	· · ·					
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4a) Of the above 5) ☐ Claim(s) 6) ☐ Claim(s) 7) ☐ Claim(s)	is/are rejected.	vn from consideration.				
Application Papers						
10) ☐ The drawing(s) f Applicant may no Replacement dra	t request that any objection to the wing sheet(s) including the correct	r. epted or b)  objected to by the l drawing(s) be held in abeyance. Sec ion is required if the drawing(s) is ob raminer. Note the attached Office	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C.	§ 119					
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>						
Attachment(s)		<u>_</u>				
Notice of References Cite     Notice of Draftsperson's     Information Disclosure Straper No(s)/Mail Date	Patent Drawing Review (PTO-948) atement(s) (PTO/SB/08)	4)  Interview Summary Paper No(s)/Mail D 5)  Notice of Informal F 6)  Other:	ate			

Application/Control Number: 10/508,759

Art Unit: 1648

## **DETAILED ACTION**

## Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions, which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claims 1-10, drawn to a process for preparing a humanized antibody comprising the steps of selecting the specificity determining residues (SDR) and grafting said SDR to at least one of the corresponding amino acid sequences into human antibody variable regions.

Group II, claims 11-14, 23, and 24 drawn to a humanized antibody.

Group III, claims 15-22, drawn to a DNA encoding the humanized antibody.

The inventions listed in groups I, II, III do not relate to a single general inventive concept under PCT Rule 13.1 because they lack the same or corresponding special technical features for the following reasons: the special technical feature of the claimed invention is the humanized antibody to HBV pre-S1 antigen and a process for preparing a humanized antibody comprising the steps of selecting the specificity determining residues (SDR) and grafting said SDR to at least one of the corresponding amino acid sequences into human antibody variable regions. Thoma (US Patent 6,020,167) discloses a humanized antibody against HBV pre-S1 antigen (MA 18/7)

Art Unit: 1648

(see Example 9). Tamura et al., (Journal of Immunology, 2000, Vol. 164, p. 1432-1441 in IDS of 8/7/2006) disclose a method for preparing a humanized antibody comprising the steps of selecting the specificity determining residues (SDR) and grafting said SDR to at least one of the corresponding amino acid sequences into human antibody variable regions (see entire document).

Since Applicant's invention does not contribute a special technical feature when viewed over the prior art they do not have a single inventive concept and thus the claims lack unity of invention. Therefore, the instant invention lacks Unity of Invention and restriction is set forth as it applies to U.S. practice.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

## Notice of Possible Rejoinder

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

Application/Control Number: 10/508,759

Art Unit: 1648

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re Brouwer and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Art Unit: 1648

## Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Agnieszka Boesen whose telephone number is 571-272-8035. The examiner can normally be reached on Monday – Friday from 9:00 AM to 5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell can be reached on 571-272-0974. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

AB Agnieszka Boesen, Ph.D.

/Stacy B. Chen/ 8-16-2007 Primary Examiner, TC1600